Interpretation of Physical Code of Chronic Disease
This system aims to prevent the risk of metabolic diseases. In addition to blood fat and blood glucose tests, it also provides subtype analysis of low-density lipoproteins, glycation end products, as well as the nutrients that affecting endothelial function, inflammatory factors and methylation metabolism tests. In addition, by using urine to analyze organic acids produced during biochemical reactions in the body can help to examine whether the metabolic function of cells using nutrients to produce energy is perfect. It can also be used to assess the risk of personal vitamin and mineral deficiency.
-
1073 Bio-META® (Urine)*55
This analysis targeted 55 organic acids, which are produced by metabolism of fatty acid, carbohydrates, amino acids, cell energy synthesis, Vitamin B, neurotransmitter, liver toxin, or by bowel harmful bacteria that excessively grows. Through this test, we can understand whether our major metabolic processes function normally or not.
-
1074 Cellular-META® (Urine)*27
This analysis targeted 27 organic acids, which are produced by metabolism of fatty acid, carbohydrates, amino acids, cell energy synthesis, Vitamin B, neurotransmitter, liver toxin, or by bowel harmful bacteria that excessively grows. Through this test, we can understand whether our major metabolic processes function normally or not.
-
1280 CardioMetabolic-META® (Blood)
Metabolic Syndrome is a condition characterized by a combination of factors such as visceral fat accumulation, abnormal glucose metabolism, hypertension, lipoprotein quality and metabolic abnormalities, and genetic predispositions. Underlying this syndrome may be clinically silent but significant issues such as adipokine imbalance, insulin resistance, endothelial dysfunction, and vascular inflammation. The more of these factors that are present simultaneously, the higher the risk of developing chronic diseases. Clinically, metabolic syndrome is used as a risk assessment tool for atherosclerosis, cardiovascular disease, and type 2 diabetes.
This assessment provides a more in-depth evaluation of the early indicators of metabolic syndrome through the following key areas : Visceral fat and glucose metabolism, Lipid and cholesterol quality and metabolism, HDL antioxidant capacity and Vascular inflammation and atherosclerosis.
Relying solely on cholesterol levels, elevated LDL-C, or the idea that “the higher HDL-C, the better” is now considered an outdated perspective in modern medicine.
-
1285 Lipoprotein-META® (Blood)
The number of people diagnosed with hyperlipidemia in the country has been increasing year by year, with statistical data showing a trend toward younger individuals being affected. Common causes of hyperlipidemia can be classified into genetic factors, disease-related conditions (such as diabetes, obesity, Cushing's syndrome, nephrotic syndrome, and hypothyroidism), as well as poor dietary habits or excessive alcohol consumption. Medical research indicates that hyperlipidemia not only contributes to cardiovascular diseases but is also associated with chronic conditions such as cerebrovascular disease, hypertension, and diabetes. Lipoprotein metabolism analysis includes tests for triglycerides, cholesterol levels, balance ratios, and lipoprotein profiling. Additional indicators related to vascular inflammation include oxidized low-density lipoprotein (oxLDL), small dense low-density lipoprotein (sdLDL), antioxidant capacity (PON1), and myeloperoxidase (MPO), all of which are effective in assessing the risk of developing coronary artery atherosclerosis.
-
1163 LDL Subfraction (Blood)
Low-density lipoprotein cholesterol (LDL-C) has long been considered a risk factor for cardiovascular disease—the higher its concentration, the greater the risk. However, in reality, standard lipid tests have less than 50% predictive accuracy for atherosclerosis. In fact, nearly 75% of patients who suffer a myocardial infarction have both LDL-C and high-density lipoprotein cholesterol (HDL-C) levels within the normal range. Therefore, additional assessment methods are needed to provide further support. LDL subfraction analysis, in addition to basic cholesterol testing, evaluates the density and particle size of lipoproteins, including triglyceride-rich lipoproteins, large buoyant LDL, and small dense LDL. This offers a more comprehensive evaluation of cardiovascular disease risk.
-
1102 Endothelial-META® (Blood)
According to the Ten Leading Cause of Death in Taiwan Statistics, vascular diseases account for 4 of them, including heart disease,Daibets ,cerebrovascular disease, and hypertension. These are all related to the health of vascular endothelium, so its function is the key for the treatment and prevention of vascular disease. This evaluation consists all the markers of endothelium, like homocysteine, folic acid, vitamin B12, arginine (the precursor of nitrogen monoxide), etc., and will reveal the detailed data of endothelial healthiness.
-
1281 Atherosclerosis Progression-META® (Blood & Urine)
Clinical studies have found that more than 30% of patients with cardiovascular disease have cholesterol levels within the normal range, indicating that while cholesterol is an important factor, it is not the only risk factor in the development of atherosclerosis. Recent research has also highlighted the critical role of inflammation in the atherosclerotic process, bringing increasing attention to inflammatory markers in the assessment of cardiovascular health risk. By evaluating the degree of inflammation through the progression of atherosclerosis, personalized health management plans can be developed to reduce the risk of disease onset.
-
0817 Bone-META® (Blood)
Assessing the nutrients required for bone formation helps evaluate the balance between bone loss and bone generation, providing a clearer picture of bone growth and the risk of osteoporosis. This information aids physicians in planning appropriate clinical treatments or nutritional supplementation programs to support and maintain bone health.